Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announces its acquisition of intellectual property and relevant assets from Molecular Assemblies (MAI). The acquisition will expand Maravai and TriLink BioTechnologies’ ability to enable customers to develop next-generation mRNA and CRISPR nucleic acid-based therapies. “Molecular Assemblies is the original leader in enzymatic oligo synthesis, with strong foundational IP. Their team has made great strides in designing and developing an enzymatic DNA synthesis platform with exciting technical advantages over traditional chemical synthesis,” said Trey Martin, CEO of Maravai LifeSciences.
Read the full article: Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies //
Source: https://www.businesswire.com/news/home/20250128647933/en/Maravai-LifeSciences-Acquires-Assets-and-Intellectual-Property-from-Molecular-Assemblies